<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVEThe C allele at the rs11212617 polymorphism in the <z:hpo ids='HP_0001251'>ataxia</z:hpo>-<z:hpo ids='HP_0001009'>telangiectasia</z:hpo>-mutated (ATM) gene has been associated with greater clinical response to <z:chebi fb="0" ids="6801">metformin</z:chebi> in people with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>We tested whether this variant modified the effect of <z:chebi fb="0" ids="6801">metformin</z:chebi> in the <z:mp ids='MP_0002055'>Diabetes</z:mp> Prevention Program (DPP), in which <z:chebi fb="0" ids="6801">metformin</z:chebi> reduced <z:mp ids='MP_0002055'>diabetes</z:mp> incidence by 31% in volunteers with <z:hpo ids='HP_0000833'>impaired glucose tolerance</z:hpo>.RESEARCH DESIGN AND METHODSWe genotyped rs11212617 in 2,994 DPP participants and analyzed its effects on <z:mp ids='MP_0002055'>diabetes</z:mp> incidence and related traits.RESULTSContrary to expectations, C carriers enjoyed no preventive advantage on <z:chebi fb="0" ids="6801">metformin</z:chebi>; their hazard ratio, compared with A carriers, was 1.17 ([95% CI 0.96-1.42], P = 0.13) under <z:chebi fb="0" ids="6801">metformin</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>There were no significant differences by genotype in <z:chebi fb="0" ids="6801">metformin</z:chebi>'s effects on insulin sensitivity, fasting <z:chebi fb="105" ids="17234">glucose</z:chebi>, glycated <z:chebi fb="0" ids="35143">hemoglobin</z:chebi>, or disposition index.CONCLUSIONSThe reported association of rs11212617 with <z:chebi fb="0" ids="6801">metformin</z:chebi> response was not confirmed for <z:mp ids='MP_0002055'>diabetes</z:mp> prevention or for effects on relevant physiologic parameters in the DPP </plain></SENT>
</text></document>